Oral Ferrous Sulphate Improves Functional Capacity on Heart Failure Patients with Iron Deficiency Anemia

Glob Heart. 2022 Nov 22;17(1):81. doi: 10.5334/gh.1151. eCollection 2022.

Abstract

Background: Iron deficiency anemia (IDA) in heart failure (HF) is associated with poor functional capacity. Several studies reported the benefit of iron therapy in HF with IDA on improving functional capacity. Therefore, we attempt to investigate the effect of oral iron supplementation on functional capacity in HF patients with IDA.

Results: A double blind randomized controlled trial was conducted in National Cardiovascular Center Harapan Kita Hospital Universitas Indonesia. A total of 54 HFREF patients with IDA were enrolled and randomized to either oral Ferrous Sulphate (FS) 200 mg three times a day or placebo with 1:1 ratio for 12 weeks. Primary outcome was functional capacity measured by a six-minute walk test. There were 41 participants completed the study (FS n = 22, placebo n = 19). Ferrous sulphate significantly improved functional capacity changes (46.23 ± 35 m vs -13.7 ± 46 m, p < 0.001, CI -86.8 to -33.2) compared with placebo groups respectively after 12 weeks intervention.

Conclusions: Oral FS supplementation for 12 weeks significantly improved functional capacity in HF patients with IDA.

Trial registration: clinicaltrials.gov, NCT02998697. Registered 14 December 2016 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02998697.

Keywords: Functional capacity; Heart failure; Iron deficiency anemia; Oral ferrous sulphate.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia, Iron-Deficiency* / drug therapy
  • Heart Failure* / complications
  • Heart Failure* / drug therapy
  • Humans
  • Iron / therapeutic use
  • Stroke Volume

Substances

  • ferrous sulfate
  • Iron

Associated data

  • ClinicalTrials.gov/NCT02998697

Grants and funding

This study was supported by Universitas Indonesia grant for International Publication. Kimia Farma company provided oral ferrous sulphate without supporting any funding and any role in the rationale, study design, conduct, analysis, or reporting.